Skip to main content Help with accessibility Skip to main navigation

Co-Trimoxazole

Indication

Low dose prophylaxis of pneumocystis jirovecii (Pneumocystis carinii) infections post-transplant
Amber level 0

Brand:

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Infection

Background

No regular routine monitoring will be required in primary care for the first 3 years of treatment. Patient monitoring will be carried out as part of tertiary care services at least monthly for the first year and every 6–12 weeks in year 2 post-transplant. For the limited number of patients still using prophylactic co-trimoxazole after 2 years post-transplant monitoring will be carried out in tertiary care services every 3–4 months in year 3.
Prophylactic co-trimoxazole treatment would not be expected to continue beyond 3 years for most patients. Where patients require prophylactic co-trimoxazole in years 4 and 5 post-transplant, consultants should liaise with primary care clinicians to ensure suitable blood monitoring arrangements are requested.

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Pending
Pending
What do the colours mean?

Last Updated: 01 - Nov - 2017